Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
MoonLake Immunotherapeutics - Class A Ordinary Shares
(NQ:
MLTX
)
9.820
-0.250 (-2.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MoonLake Immunotherapeutics - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 11, 2023
Via
Benzinga
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
September 06, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
August 31, 2023
Via
Benzinga
Expert Ratings for MoonLake
August 31, 2023
Via
Benzinga
10 Analysts Have This to Say About MoonLake
August 14, 2023
Via
Benzinga
Analyst Expectations for MoonLake's Future
July 26, 2023
Via
Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
August 31, 2023
Via
Benzinga
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
Via
InvestorPlace
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
Where MoonLake Stands With Analysts
July 03, 2023
Via
Benzinga
Why MoonLake Immunotherapeutics Stock Skyrocketed This Week
June 29, 2023
Positive mid-stage results fueled a spike in the biotech's shares this week.
Via
The Motley Fool
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 25, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More
July 18, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile'
July 17, 2023
HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75
Via
Benzinga
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
July 17, 2023
Benzinga
Via
Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
July 17, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...
Via
Benzinga
10 Short Squeeze Stocks To Watch: Asset Entities, Lightning eMotors, Bullfrog AI, Carvana And More
July 10, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
$40M Bet On MoonLake Immunotherapeutics? Check Out These 3 Stocks Insiders Are Buying
July 06, 2023
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 04, 2023
Via
Benzinga
10 Short Squeeze Stocks To Watch: A Leader That Moved Up 392 Positions, Intuitive Machines, Toro And More
July 03, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
MarketBeat Week in Review – 6/26 - 6/30
July 01, 2023
Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week.
Via
MarketBeat
Topics
Economy
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
June 30, 2023
Major indexes rebounded strongly and many stocks flashed buy signals.
Via
Investor's Business Daily
MoonLake Immunotherapeutics Makes a Moonshot on Trials
June 28, 2023
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results.
Via
MarketBeat
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
June 28, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today
June 27, 2023
The heavily bullish sentiment on the company only grew on the second trading day of the week.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 27, 2023
Via
Benzinga
MoonLake Immunotherapeutics, Applied Digital And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 27, 2023
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of Phase 2 Trial
June 26, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.